Sydney-based biopharmaceutical firm, Kazia Therapeutics Limited, has been making strides in the development of anti-cancer drugs. Its leading development candidate, Paxalisib, is a brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which offers promising potential as a therapy for glioblastoma. In addition, the company is currently in the developmental stages of EVT801, an investigational drug that could potentially treat multiple forms of cancer. Prior to November 2017, Kazia Therapeutics was known as Novogen Limited. Established in 1994, the company has since focused its efforts on the development of oncology-related treatments.
Kazia Therapeutics Limited's ticker is KZIA
The company's shares trade on the NASDAQ stock exchange
They are based in Barangaroo, Australia
There are 11-50 employees working at Kazia Therapeutics Limited
It is https://www.kaziatherapeutics.com/home
Kazia Therapeutics Limited is in the Healthcare sector
Kazia Therapeutics Limited is in the Biotechnology industry
The following five companies are Kazia Therapeutics Limited's industry peers: